Literature DB >> 7567644

Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature.

G V Coppa1, O Gabrielli, L Zampini, P Pierani, P L Giorgi, A M Jezequel, F Orlandi, R Miniero, A Busca, T De Luca.   

Abstract

A patient with Hunter syndrome, or mucopolysaccharidosis type II (MPS-osis II), was subjected to bone marrow transplantation (BMT), at the age of 2 9/12 years. A two-year follow-up ensued to the purpose of comparing clinical, biochemical, neuropsychologic status pre- and post-BMT. From the clinical standpoint, a complete normalization of hepatosplenomegaly was observed. In addition the skin decreased in thickness and joint mobility improved. The echocardiography showed normalization of left ventricle size. With the exception of verbal capabilities, there was no further deterioration of the neuropsychologic profile. The ultrastructural examination of the liver showed an almost total disappearance of storage material. Normal iduronate sulfatase levels in leukocytes and lymphoblasts were constantly found after BMT. A qualitative and quantitative improvement in urinary glycosaminoglycan (GAG) excretion was also found. The effectiveness of the BMT in our patient is also assessed in the context of the few cases of MPS-osis II that have been reported to date. A final evaluation of the efficacy of BMT in MPS-osis II will be possible only when a higher number of patients, diagnosed as early as possible and transplanted within the first months of life, can be followed-up for more extended periods of time.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567644

Source DB:  PubMed          Journal:  Pediatr Med Chir        ISSN: 0391-5387


  6 in total

1.  Long-term follow-up following bone marrow transplantation for Hunter disease.

Authors:  A Vellodi; E Young; A Cooper; V Lidchi; B Winchester; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 2.  Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Authors:  Claire Horgan; Simon A Jones; Brian W Bigger; Robert Wynn
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

3.  Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.

Authors:  Bianca Link; Louise Lapagesse de Camargo Pinto; Roberto Giugliani; James Edmond Wraith; Nathalie Guffon; Elke Eich; Michael Beck
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23

4.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

5.  Glycosaminoglycan storage disorders: a review.

Authors:  Maria Francisca Coutinho; Lúcia Lacerda; Sandra Alves
Journal:  Biochem Res Int       Date:  2011-10-05

Review 6.  Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.

Authors:  David Ah Whiteman; Alan Kimura
Journal:  Drug Des Devel Ther       Date:  2017-08-23       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.